Ad Scientiam

Ad Scientiam develops and clinically validates digital biomarkers, which are measured through patients' smartphones and connected devices and processed with proprietary algorithms. Its products are software medical devices (SaMD) for monitoring diseases such as multiple sclerosis, myasthenia gravis, neuromyelitis optica and cystic fibrosis. MSCopilot is listed as available, while MyoSense 360, NMOSDCopilot, ME&MG and MuCopilot are in clinical investigation or under development and validation.

The company offers patients mobile applications for at-home self-assessments and healthcare professionals dashboards with patient data transferred in real time. It also works with clinical studies, and its website lists 120+ partner centers, 1500+ patients, 350+ healthcare professionals, 10 clinical studies and 7 countries.

Founded in 2013 and headquartered in Paris, where it is located at Digital Village in the 13th arrondissement. In 2026 it announced the first patient enrolled in the HARMONY 360 study, conducted with Merck KGaA, Darmstadt, Germany, to explore remote digital monitoring of generalized myasthenia gravis with MyoSense 360.

Product: Software medical devices (SaMD) for remote disease monitoring: a patient mobile app with clinical-grade self-assessment tests, plus a healthcare professional dashboard.